Liyun Ni

2.5k total citations
20 papers, 1.1k citations indexed

About

Liyun Ni is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Liyun Ni has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hepatology, 5 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in Liyun Ni's work include Hepatitis C virus research (9 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Liyun Ni is often cited by papers focused on Hepatitis C virus research (9 papers), HIV/AIDS drug development and treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Liyun Ni collaborates with scholars based in United States, Australia and Canada. Liyun Ni's co-authors include C.E. Davis, Heejung Bang, Diana M. Brainard, Debra Zack, Evguenia S. Svarovskaia, John G. McHutchison, Anuj Gaggar, G. Mani Subramanian, Francis X. Burch and Alan Kivitz and has published in prestigious journals such as The Lancet, JAMA and Gastroenterology.

In The Last Decade

Liyun Ni

19 papers receiving 1.1k citations

Peers

Countries citing papers authored by Liyun Ni

Since Specialization

Citations

This map shows the geographic impact of Liyun Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liyun Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liyun Ni more than expected).

Fields of papers citing papers by Liyun Ni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liyun Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liyun Ni. The network helps show where Liyun Ni may publish in the future.

Co-authorship network of co-authors of Liyun Ni

This figure shows the co-authorship network connecting the top 25 collaborators of Liyun Ni. A scholar is included among the top collaborators of Liyun Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liyun Ni. Liyun Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	WED-310 A mathematical viral load model characterises the exposure- response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologic response 2025 ·Journal of Hepatology ·(unknown), (unknown), Nieves Vélez de Mendizábal, Luzelena Caro, (unknown), Amos Lichtman, (unknown), Renée-Claude Mercier, Liyun Ni, Yang Liu, Hongmei Mo, Ana Ruiz-Garcı́a	1
2	Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment 2022 ·Alimentary Pharmacology & Therapeutics ·Mark Sulkowski, Laura Telep, Massimo Colombo, François Durand, K. Rajender Reddy, Eric Lawitz, Marc Bourlière, (unknown), (unknown), Liyun Ni, (unknown), Heribert Ramroth, Anuj Gaggar, Anand P. Chokkalingam, Meghan E. Sise	5
3	Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies 2022 ·British Journal of Clinical Pharmacology ·Amy Meng, (unknown), Cara Nelson, Liyun Ni, (unknown), Francesco Bellanti, Peter Chang, (unknown), Brian P. Kearney, Beatrix Bartók, Anita Mathias	7
4	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies 2018 ·Open Forum Infectious Diseases ·Jason Grebely, Jordan J. Feld, David Wyles, Mark Sulkowski, Liyun Ni, (unknown), (unknown), (unknown), Luisa M. Stamm, Robert H. Hyland, John McNally, Diana M. Brainard, Ira M. Jacobson, Stefan Zeuzem, Marc Bourlière, Graham R. Foster, Nezam H. Afdhal, Gregory J. Dore	33
5	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, NS5A treatment‐naïve patients: Findings from two randomized trials 2017 ·Liver International ·Edward Tam, Anne F. Luetkemeyer, Parvez Mantry, Sanjaya K. Satapathy, Peter Ghali, Min‐Hee Kang, Richard Haubrich, (unknown), Liyun Ni, Grégory Camus, (unknown), Lorenzo Rossaro, Bill Guyer, Robert S. Brown, (unknown)	11
6	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study 2015 ·The Lancet ·Jean‐Michel Molina, Chloe Orkin, David Iser, (unknown), Mark Nelson, Christoph Stephan, Benedetta Massetto, Anuj Gaggar, Liyun Ni, Evguenia S. Svarovskaia, Diana M. Brainard, G. Mani Subramanian, John G. McHutchison, Massimo Puoti, Jürgen K. Rockstroh	133
7	O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials 2015 ·Journal of the International AIDS Society ·Jorge Santana, Juergen Rockstroh, Massimo Puoti, M. Rodríguez‐Torres, Douglas T. Dieterich, Anuj Gaggar, Liyun Ni, Benedetta Massetto, Evguenia S. Svarovskaia, Diana M. Brainard, Mani Subramanian, John G. McHutchison, Susanna Naggie, Chloe Orkin, Jean‐Michel Molina, Mark Sulkowski	0
8	P14: Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV co-infected patients (PHOTON-1) 2014 ·Journal of the International AIDS Society ·M. Rodríguez‐Torres, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Liyun Ni, (unknown), (unknown), (unknown), (unknown)	4
9	239 Successful Retreatment With Sofosbuvir-Containing Regimens for HCV Genotype 2 or 3 Infected Patients Who Failed Prior Sofosbuvir Plus Ribavirin Therapy 2014 ·Gastroenterology ·Lisa M. Nyberg, Jacob Lalezari, Liyun Ni, Brian Doehle, Bittoo Kanwar, Diana M. Brainard, G. Mani Subramanian, William T. Symonds, John G. McHutchison, M. Rodríguez‐Torres	2
10	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection 2014 ·JAMA ·Mark Sulkowski, Susanna Naggie, Jacob Lalezari, W. Jeffrey Fessel, Karam Mounzer, Margaret C. Shuhart, Anne F. Luetkemeyer, David M. Asmuth, Anuj Gaggar, Liyun Ni, Evguenia S. Svarovskaia, Diana M. Brainard, William T. Symonds, G. Mani Subramanian, John G. McHutchison, M. Rodríguez‐Torres, Douglas T. Dieterich	188
11	A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee 2011 ·Arthritis Research & Therapy ·Stanley Cohen, Susanna Proudman, Alan Kivitz, Francis X. Burch, John P. Donohue, Deborah Burstein, Yu‐Nien Sun, Christopher Banfield, Michael S. Vincent, Liyun Ni, Debra Zack	197
12	Group Sequential Methods and Software Applications 2011 ·The American Statistician ·Li Zhu, Liyun Ni, Bin Yao	12
13	A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis 2010 ·Arthritis Research & Therapy ·Mario H. Cardiel, Paul P. Tak, W. Bensen, Francis X. Burch, Šárka Forejtová, J Badurski, Tarundeep Kakkar, (unknown), Liyun Ni, (unknown), Angelika Jahreis, Debra Zack	21
14	Single-Dose, First-in-Human Study Of AMG 853: Pharmacokinetics, Pharmacodynamics, And Safety In Healthy Adults 2010 ·Christopher Banfield, Jane R. Parnes, Maurice G. Emery, Liyun Ni, Nan Zhang, Peter Hodsman	3
15	An Extended Terminal Half-Life for Darbepoetin Alfa 2006 ·Clinical Pharmacokinetics ·Desmond Padhi, Liyun Ni, Blaire Cooke, Rafael Marino, Graham Jang	31
16	Bioequivalence of Liquid and Reconstituted Lyophilized Etanercept Subcutaneous Injections 2006 ·The Journal of Clinical Pharmacology ·John T. Sullivan, Liyun Ni, (unknown), Margaret Salfi, Paul M. Peloso	10
17	Response to Henneicke-von-Zepelin and Harri Hemilä's comment 2005 ·Contemporary Clinical Trials ·(unknown), Liyun Ni, C.E. Davis	7
18	Assessment of blinding in clinical trials 2004 ·Controlled Clinical Trials ·Heejung Bang, Liyun Ni, C.E. Davis	413
19	Factors affecting increasing radiation dose for mammography in North Carolina from 1997 through 2001 2004 ·Academic Radiology ·Etta D. Pisano, (unknown), Liyun Ni, Yun Li, (unknown), Rachel Johnson, (unknown), Elodia B. Cole, Cherie M. Kuzmiak, Marcia Koomen, Dag Pavić	7
20	Pharmacokinetics of Ibuprofen Enantiomers in Children with Cystic Fibrosis 2000 ·The Journal of Clinical Pharmacology ·Jennifer Dong, Liyun Ni, (unknown), George Retsch‐Bogart, Philip C. Smith	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact